Hypotonia–cystinuria 2p21 deletion syndrome: Intrafamilial variability of clinical expression

Atif Towheed, Christian L. Hietanen, Vasudeva G. Kamath, Larry N. Singh, Angela Ho, Kristin Engelstad, Kayla Cornett, Jacqueline Montes & Darryl De Vivo

1Touro College of Osteopathic Medicine, Middletown, NY, 10940
2Children’s Hospital of Philadelphia Research Institute, Philadelphia, PA, 19104
3Department of Neurology, Columbia University Irving Medical Center, New York, NY, 10032
4Department of Rehabilitation and Regenerative Medicine (Physical Therapy), Columbia University Irving Medical Center, New York, NY, 10032
5Department of Neurology and Pediatrics, Columbia University Irving Medical Center, New York, NY, 10032

Correspondence
Darryl De Vivo, Department of Neurology and Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA.
Tel: 1-212-305-5244; Fax: 212-305-7036; E-mail: dcd1@cumc.columbia.edu

Abstract

Two siblings presented similarly with congenital hypotonia, lactic acidosis, and failure to thrive. Later in childhood, the brother developed cystinuria and nephrolithiasis whereas the older sister suffered from cystinuria and chronic neurobehavioral disturbances. Biopsied muscle studies demonstrated deficient cytochrome c oxidase activities consistent with a mitochondrial disease. Whole exome sequencing (WES), however, revealed a homozygous 2p21 deletion involving two contiguous genes, SLC3A1 (deletion of exons 2-10) and PREPL (deletion of exons 2-14). The molecular findings were consistent with the hypotonia–cystinuria 2p21 deletion syndrome, presenting similarly in infancy with mitochondrial dysfunction but diverging later in childhood and displaying intrafamilial phenotypic variability.

Introduction

Homozygous deletion of chromosome 2p21, containing two closely located genes, SLC3A1, and PREPL (Fig. 1), has been linked to the hypotonia–cystinuria syndrome (HCS; OMIM #606407). Symptoms include generalized hypotonia at birth, failure to thrive, cystinuria, and growth retardation. The deletion size typically ranges from 23.8 to 75.5 kb. Taroni (2019) reported that the HCS is a rare disease with only 26 cases reported to date resulting from eight different deletions. From the published reports, HCS is not usually associated with mitochondrial dysfunction. Literature search yielded two previous reports of HCS with mitochondrial dysfunction (Parvari, 2001 and Zaffanello, 2003).

SLC3A1 encodes the heavy chain subunit of the cystine and dibasic amino acid transporters in the renal proximal tubule and small intestine. Inactivation causes cystinuria type 1 (OMIM 220100). The SLC3A1 gene spans 46 kb and has 10 exons. Cystinuria is characterized by a defect in resorption of cystine, ornithine, lysine, and arginine. High concentrations of cystine in the distal tubule results in the precipitation of cystine stones. PREPL is a prolyl oligopeptidase-like protein homologous to the prolyl oligopeptidase family. All proteins in this family have been implicated in various clinical conditions; prolyl endopeptidase (PREP; OMIM 600400), oligopeptidase B (OpdB) (role in host cell invasion by Trypanosoma cruzi, Chagas disease), acylaminoacyl-peptidase (APEH; OMIM 102645), and dipeptidase IV (DPPIV; OMIM 102720). Isolated loss of PREPL gene has been implicated in congenital myasthenic syndrome-22 (CMS22; OMIM 616224).

We report two siblings with a similar early clinical presentation consistent with mitochondrial disease. Muscle biopsy revealed partial cytochrome c oxidase deficiency. The later clinical courses in the two siblings diverged with severe nephrolithiasis dominating the one case and neurobehavioral disturbances dominating the other. We offer some speculations regarding the intrafamilial variability of the clinical presentations during later development.
Patients and Methods

Clinical presentation

Patient 1

Patient 1, a 19-year-old male with a history of failure to thrive, hypotonia, developmental delay, and severe gastroesophageal reflux, required a gastrostomy in infancy. Additional findings included lactic acidosis, mild dysmorphism of facial features, a nasal speech pattern consistent with velopharyngeal insufficiency and color blindness.

At age 7 years, a chest x-ray incidentally revealed kidney stones prompting further investigation. Twenty-four-hour urine evaluation confirmed high cystine excretion. The patient later required percutaneous nephrolithotomy for removal of 19 stones (100% cystine composition) leading to a diagnosis of cystinuria and urolithiasis. Poor renal function prompted aggressive treatment with Polycitra-K and Sulfá prophylaxis. A muscle biopsy confirmed partial cytochrome c oxidase deficiency (40.61% of control).

Generalized muscle weakness and exertional fatigue became evident with increasing physical demands requiring wheelchair for more sustained activities. Growth hormone (GH) therapy was started at age 12 years when he was below the 5th percentile for height. Five years later height was at the 17th percentile. Academic and social concerns worsened during higher education. At age 14 years, he was diagnosed with mild autism spectrum disorder (ASD). Currently, he is doing well academically and anticipating entering college shortly.

Genetic analysis using WES for Patient 1 revealed nuclear mutations in Chr2:44503092-44578898del (homozygous) (SLC3A1:E2_10del/ PREPL:E2_14del homozygous), TTN c.59344A>C (p.K19782Q) and c.50026A>C (p.T16676P) in trans, and OR5H14 c.4G>A (p.E3K) homozygous. Mitochondrial sequencing revealed MTRNR1 m.884T>C 2.1% heteroplasmy VUS but was
negative for large deletions and other known pathogenic mutations.

The family history is remarkable with his sister (Patient 2) initially presenting with similar symptoms. Both maternal and paternal family members are of Dutch descent (Fig. 2). WES analysis confirmed the parents as heterozygous carriers for the 2p21 microdeletion consistent with an autosomal recessive pattern of inheritance.

**Patient 2**

Patient 2 is a 23-year-old female with a history of hypotonia, lactic acidosis, feeding, and gastrointestinal motility problems consistent with congenital onset mitochondrial disease. She suffered developmental delays in early childhood with generalized muscle weakness, mild gait disturbance, exercise intolerance, fatigue, and nasal voice. The patient later demonstrated serious neurobehavioral disturbances and learning difficulties. She was diagnosed with ASD, complicated by comorbid features of attention deficit hyperactivity disorder, obsessive-compulsive disorder, and chronic anxiety. The medications included lisdexamfetamine, fluoxetine, omeprazole, 1-thyroxine, vitamin B12, coenzyme Q10, biotin, and GH.

In contrast to her brother, Patient 2 developed cystinuria much later and remains free of renal calculi. Muscle biopsy revealed 29% cytochrome c oxidase activity compared to the control. G-banding karyotype analysis proved unremarkable likely due to poor resolution.

![Figure 2. Family pedigree.](image-url)
WES analysis revealed the same microdeletion found in her brother. In addition, she had distinct nuclear mutations involving GRIN3A c.2309G>A (p.G770D) and c.3332G>A (p.R1111Q) (heterozygous) and USP25 c.2929A>C (p.K977Q) (homozygous). Other than a benign polymorphism in mt tRNA-Lys m.8251G>A, mitochondrial genome analysis was unremarkable.

Both patients were evaluated biannually for 7 years and the 6-minute walk test (6MWT) was used to monitor ambulatory function and endurance.13 Distance walked continued to improve, but both patients consistently underperformed walking approximately 150 meters less on average than predicted (Fig. 3). Neither patient displayed laboratory evidence of fatigue. Patient 1 had a normal average fatigue index of −2.4% over ten 6MWTs. Patient 2 also had a normal average fatigue index of 2.4% over nine 6MWTs. Additional exercise testing performed by Patient 1 at ages 15 and 16 years, revealed aerobic capacity that was more than 50% below average (VO2 peak = 20.1 and 22.0 mL/kg/min, respectively) and diminished local muscle oxygen uptake during exercise using near infrared spectroscopy (NIRS).14,15 NIRS is a noninvasive method to determine oxygen saturation in tissues which quantifies muscle oxygen uptake and oxidative capacity from an exercise tolerance test.

Discussion

The patients presented here have homozygous deletions of SLC3A1 and PREPL which according to Chabrol et al. and Bartholdi et al. would be classified as HCS. Chabrol et al. reported respiratory chain deficiency observed in all patients with 2p21 deletion syndrome patients.16,17 Remarkably, the above clinical presentations are inconsistent with this report of HCS as the clinical evidence for a mitochondrial disorder in HCS is uncommon.2

In contrast, the presence of mitochondrial disease is relatively common in “2p21 microdeletion syndrome” which involves the deletion of at least four contiguous genes on chromosome 2, SLC3A1, PREPL, PPM1B, and CAMKMT. PPM1B, and CAMKMT mutations were not found in these patients.18 The two siblings were initially diagnosed with partial cytochrome c oxidase deficiency. Subsequent WES and cSNP-array confirmed the homozygous microdeletion of SLC3A1 and PREPL. Therefore, these findings confirmed the diagnosis of HCS presenting atypically with mitochondrial dysfunction and partial cytochrome c oxidase deficiency.

Mitochondrial dysfunction in the setting of SLC3A1 and PREPL mutations is intriguing but not easily explained. Neither gene, has been shown to play a direct role in mitochondrial function. We do wonder if mitochondrial dysfunction could be the result of a blunted response to oxidative stress. Reduced SLC3A1 expression may affect glutathione (GSH) synthesis as cysteine serves as the rate-limiting precursor for GSH synthesis. Dysregulation of GSH could contribute to increased cellular vulnerability to oxidative stress.19 Further studies will be necessary to pursue this speculation.
HCS syndrome is generally accompanied by GH deficiency. According to the current understanding of familial isolated GH deficiencies, there are at least four possibilities. However, none of these possibilities explain the GH deficiency in this clinical setting.

Although the two patients have the same microdeletion, their clinical presentation later diverged significantly. These differences could be attributed, at least in part, to the additional mutations in the respective genetic backgrounds. For example, Patient 2 has a mutation in GRIN3A which could potentially impact synaptic elements in the brain contributing to severe neurobehavioral issues.

The absence of renal stones and late presentation of cystinuria in Patient 2 also is perplexing. We would expect Patient 2 to present with urolithiasis and cystinuria earlier. The difference in clinical symptoms of urolithiasis in Patient 1 versus Patient 2 despite sharing the same deletion supports the observation of intrafamilial phenotypic variability; but the mechanism underlying this variability remains obscure. We speculate that oxidative stress may contribute but direct measures of GSH will be necessary to characterize the underlying mechanisms.

Gender could potentially play a role in the differences observed between the two siblings. According to a report by Nagamori et al., heterodimeric partners of basic amino acid transporters in the proximal kidney tubule were found to be expressed in a pattern determined by the biological sex. This study suggests a modulating role of estrogen on the tubular amino acid transport.

In summary, HCS is a complex genetic syndrome complicated by the variable presentation of clinical symptoms in early life and kidney dysfunction with urolithiasis later in life. The mechanism underlying mitochondrial dysfunction remains obscure. We speculate that oxidative stress may contribute but direct measures of GSH will be necessary to support this speculation. Management of GH deficiency clearly is indicated but, again, the mechanism underlying this endocrine disturbance needs to be elucidated.

Acknowledgment

The authors are thankful to the family for their time and continued support.

Conflict of Interest

The authors are not aware of any conflict of interest involved in this report.

Funding Information

No funding information provided.

References

1. Jaeken J, Martens K, Franco I, et al. Deletion of PREPL, a gene encoding a putative serine oligopeptidase, in patients with hypotonia-cystinuria syndrome. Am J Hum Genet. 2006;78(1):38-51.
2. Taroni F, Capone V, Berrettini A, De Marco EA, Manzoni GA, Montini G. A case of hypotonia-cystinuria syndrome with genito-urinary malformations and extrarenal involvement. Front Pediatr. 2019;7:127.
3. Parvari R, Brodiansky I, Elpeleg O, Moses S, Landau D, Hershkovitz E. A recessive contiguous gene deletion of chromosome 2p16 associated with cystinuria and a mitochondrial disease. Am J Hum Genet. 2001;69(4):869-875.
4. Zaffanello M, Beghini R, Zamboni G, Fanos V. A sporadic case of cystinuria, respiratory chain and growth hormone deficiencies. Pediatr Nephrol. 2003;18(8):846-847.
5. Chabrol B, Martens K, Meulemans S, et al. Deletion of C2orf34, PREPL and SLC3A1 causes atypical hypotonia-cystinuria syndrome. J Med Genet. 2008;45(5):314-318.
6. Calonge MJ, Gasparini P, Chillaron J, et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet. 1994;6(4):420-425.
7. Font-Llitjos M, Jimenez-Vidal M, Bisceglia L, et al. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J Med Genet. 2005;42(12):58-68.
8. Pras E, Sood R, Raben N, Aksentijevich I, Chen X, Kastner DL. Genomic organization of SLC3A1, a transporter gene mutated in cystinuria. Genomics. 1996;36(1):163-167.
9. Purroy J, Bisceglia L, Calonge MJ, et al. Genomic structure and organization of the human rBAT gene (SLC3A1). Genomics. 1996;37(2):249-252.
10. Polgar L. The prolyl oligopeptidase family. Cell Mol Life Sci. 2002;59(2):349-362.
11. Caler EV, Vaena de Avalos S, Haynes PA, Andrews NW, Burleigh BA. Oligopeptidase B-dependent signaling mediates host cell invasion by Trypanosoma cruzi. EMBO J. 1998;17(17):4975-4986.
12. Regal I, Shen XM, Selcen D, et al. PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome. Neurology. 2014;82(14):1254-1260.
13. McKay MJ, Baldwin JN, Ferreira P, et al. Reference values for developing responsive functional outcome measures across the lifespan. Neurology. 2017;88(16):1512-1519.
14. Montes J, Goodwin AM, McDermott MP, et al. Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8(5):1086-1095.
15. Rolfe P. In vivo near-infrared spectroscopy. Annu Rev Biomed Eng. 2000;2:715-754.
16. Chabrol B, Martens K, Meulemans S, et al. Deletion of C2orf34, PREPL and SLC3A1 causes atypical hypotonia-cystinuria syndrome. BMJ Case Rep. 2009;2009.
17. Martens K, Heulens I, Meulemans S, et al. Global distribution of the most prevalent deletions causing hypotonia-cystinuria syndrome. Eur J Hum Genet. 2007;15(10):1029-1033.
18. Bartholdi D, Asadollahi R, Oneda B, et al. Further delineation of genotype-phenotype correlation in homozygous 2p21 deletion syndromes: first description of patients without cystinuria. Am J Med Genet A. 2013;161A(8):1853-1859.
19. Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30(1-2):1-12.
20. Alatzoglou KS, Webb EA, Le Tissier P, Dattani MT. Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. Endocr Rev. 2014;35 (3):376-432.
21. Lahme S, Bichler KH, Eggermann T, Lang F. Genomic and functional investigations of mutations of the SLC3A1 gene in cystinuria. Urol Int. 2002;69(3):207-211.
22. Parvari R, Gonen Y, Alshafee I, Buriakovsky S, Regev K, Hershkovitz E. The 2p21 deletion syndrome: characterization of the transcription content. Genomics. 2005;86(2):195-211.
23. Nagamori S, Wiriyasermkul P, Guarch ME, et al. Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci USA. 2016;113 (3):775-780.
24. Hahne F, Ivanek R. Visualizing genomic data using gviz and bioconductor. Methods Mol Biol. 2016;1418:335-351.